Peptides DB
Research-centric peptide and protocol reference hub
NatureSeptember 28, 2026Safety

Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

Reported by Nature. Read the original →

What the story says

The story reports on a study comparing the efficacy and safety of tirzepatide and semaglutide for treating obesity or overweight in patients who do not have type 2 diabetes.

Summarised by a model from Nature's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

  • Semaglutide has 60 studies on file, 32 of them in humans, the newest published 2026.
  • Tirzepatide has 29 studies on file, 16 of them in humans, the newest published 2026.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.